Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Select Drug Profiles
FDA Approvals
,
Select Drug Profiles
Rydapt First Drug in Decades Approved by the FDA for Acute Myeloid Leukemia
Read More
FDA Approvals
,
Select Drug Profiles
Stivarga First Drug in a Decade Approved by the FDA for Liver Cancer
Read More
FDA Approvals
,
Select Drug Profiles
Atezolizumab Approved as First-Line Treatment for Advanced Bladder Cancer in Some Patients
Read More
FDA Approvals
,
Select Drug Profiles
Bavencio, a PD-L1 Inhibitor, First Nonchemotherapy Drug Approved for Merkel-Cell Carcinoma
Read More
FDA Approvals
,
Select Drug Profiles
Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
Read More
FDA Approvals
,
Select Drug Profiles
Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL
Read More
FDA Approvals
,
Select Drug Profiles
Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Read More
Breast Cancer
,
FDA Approvals
,
Select Drug Profiles
Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Nuplazid First Drug Approved for Hallucinations and Delusions Associated with Parkinson’s Disease
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Zynbrita a New Treatment Available for Relapsing Multiple Sclerosis
Read More
6
7
8
9
10
11
12
Page 9 of 13
Results 81 - 90 of 121